Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
7 pending office actions • 2 clients • 7 examiners • 4 art units • 0 of 7 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
K&L Gates LLP-Chicago focuses on Chemistry & Materials. It has 34213 career applications. The firm has a resolved allowance rate of 84.55 percent. It averages 3.82 office actions per allowance. There are 171 pending office actions.
The 84.55 percent allowance rate is derived from 34213 career applications. The average of 3.82 office actions per allowance reflects the typical interaction with the patent office. The 171 pending office actions represent the firm's current workload in chemistry.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (71%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEVY, BRANDON WILLIAM | 1 | 62.7% | +46.3% |
| MARSH, OWEN LEWIS | 1 | 66.7% | +50.0% |
| SHARMA, YASHITA | 1 | 81.8% | +24.6% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| TOTH, KAREN E | 1 | 46.4% | +25.8% |
| MANNAN, MIKAIL A | 1 | 68.5% | +23.5% |
| EISEMAN, LYNSEY C | 1 | 49.1% | +39.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18539423 | BIORESORBABLE CORNEAL IMPLANTS | SHARMA, YASHITA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18663943 | PHOTOACTIVATION SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING TREATMENTS | MARSH, OWEN LEWIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 13438705 | CONTROLLED CROSS-LINKING INITIATION AND CORNEAL TOPOGRAPHY FEEDBACK SYSTEMS FOR DIRECTING CROSS-LINKING | EISEMAN, LYNSEY C | 20d |
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | LEVY, BRANDON WILLIAM | — |
| 18663943 | PHOTOACTIVATION SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING TREATMENTS | MARSH, OWEN LEWIS | — |
| 18539423 | BIORESORBABLE CORNEAL IMPLANTS | SHARMA, YASHITA | — |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | BASQUILL, SEAN M | — |
| 17844497 | INTRAOCULAR PHYSIOLOGICAL SENSOR | TOTH, KAREN E | — |
| 17125466 | OCULAR TISSUE PERFORATION DEVICE | MANNAN, MIKAIL A | — |
| Art Unit | Apps |
|---|---|
| 3774 | 2 |
| 1614 | 1 |
| 3791 | 1 |
| 3796 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | Glaukos Corporation | LEVY, BRANDON WILLIAM | §103 | Non-Final OA | — | Pending | Oct 11, 2024 | |
| 18663943 | PHOTOACTIVATION SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING TREATMENTS | Avedro, Inc. | MARSH, OWEN LEWIS | §102§103§112Other | Non-Final OA | — | Pending | May 14, 2024 | |
| 18539423 | BIORESORBABLE CORNEAL IMPLANTS | Avedro, Inc. | SHARMA, YASHITA | 3774 | §103 | Final Rejection | — | Pending | Dec 14, 2023 |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | Glaukos Corporation | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Jul 26, 2023 |
| 17844497 | INTRAOCULAR PHYSIOLOGICAL SENSOR | Glaukos Corporation | TOTH, KAREN E | 3791 | §112 | Final Rejection | — | Pending | Jun 20, 2022 |
| 17125466 | OCULAR TISSUE PERFORATION DEVICE | Glaukos Corporation | MANNAN, MIKAIL A | 3774 | §103 | Final Rejection | — | Pending | Dec 17, 2020 |
| 13438705 | CONTROLLED CROSS-LINKING INITIATION AND CORNEAL TOPOGRAPHY FEEDBACK SYSTEMS FOR DIRECTING CROSS-LINKING | Avedro, Inc. | EISEMAN, LYNSEY C | 3796 | §103 | Non-Final OA | 20d | Pending | Apr 03, 2012 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial